252 related articles for article (PubMed ID: 29374719)
61. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
62. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
[TBL] [Abstract][Full Text] [Related]
63. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
[TBL] [Abstract][Full Text] [Related]
64. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Cardoso F; Canon JL; Amadori D; Aldrighetti D; Machiels JP; Bouko Y; Verkh L; Usari T; Kern KA; Giorgetti C; Dirix L
Breast; 2012 Dec; 21(6):716-23. PubMed ID: 23022045
[TBL] [Abstract][Full Text] [Related]
65. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Yardley DA; Dickson N; Drosick D; Earwood C; Inhorn R; Murphy P; Hainsworth JD
Clin Breast Cancer; 2016 Jun; 16(3):180-7. PubMed ID: 26943991
[TBL] [Abstract][Full Text] [Related]
66. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC; van Tinteren H; de Groot SM; Ten Tije AJ; de Graaf H; Portielje JE; Jager A; Honkoop A; Linn SC; Kroep JR; Erdkamp FL; Hamberg P; Imholz AL; van Rossum-Schornagel QC; Heijns JB; van Leeuwen-Stok AE; Sleijfer S
Cancer; 2016 Oct; 122(19):2961-70. PubMed ID: 27315546
[TBL] [Abstract][Full Text] [Related]
67. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
68. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D; Wesolowski R; Zelinskas S; Pinette A; Benner B; Schwarz E; Savardekar H; Johnson C; Stiff A; Yu L; Macrae E; Lustberg M; Mrozek E; Ramaswamy B; Carson WE
Cancer Control; 2024; 31():10732748241250189. PubMed ID: 38797949
[TBL] [Abstract][Full Text] [Related]
69. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer.
Theodoulou M; Batist G; Campos S; Winer E; Welles L; Hudis C
Clin Breast Cancer; 2009 May; 9(2):101-7. PubMed ID: 19433391
[TBL] [Abstract][Full Text] [Related]
70. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
71. Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.
Sakaguchi K; Nakatsukasa K; Taguchi T
Anticancer Res; 2016 Dec; 36(12):6515-6519. PubMed ID: 27919976
[TBL] [Abstract][Full Text] [Related]
72. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
Acevedo-Gadea C; Hatzis C; Chung G; Fishbach N; Lezon-Geyda K; Zelterman D; DiGiovanna MP; Harris L; Abu-Khalaf MM
Breast Cancer Res Treat; 2015 Feb; 150(1):157-67. PubMed ID: 25687356
[TBL] [Abstract][Full Text] [Related]
73. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
Ozaki Y; Aoyama Y; Masuda J; Inagaki L; Kawai S; Shibayama T; Maeda T; Kurata M; Yoshida K; Saeki S; Hosonaga M; Fukada I; Hara F; Kobayashi T; Kobayashi K; Miyake S; Takano T; Ueno T; Ohno S
BMC Cancer; 2022 Jan; 22(1):36. PubMed ID: 34983437
[TBL] [Abstract][Full Text] [Related]
74. Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis.
Lv S; Wang Y; Sun T; Wan D; Sheng L; Li W; Zhu H; Li Y; Lu J
Oncol Res Treat; 2018; 41(7-8):450-455. PubMed ID: 29902791
[TBL] [Abstract][Full Text] [Related]
75. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer.
Honma Y; Shimada Y; Takashima A; Iwasa S; Kato K; Hamaguchi T; Yamada Y; Taniguchi H; Sekine S; Kushima R
Int J Clin Oncol; 2014 Oct; 19(5):863-70. PubMed ID: 24218279
[TBL] [Abstract][Full Text] [Related]
77. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
78. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Wardley A; Cortes J; Provencher L; Miller K; Chien AJ; Rugo HS; Steinberg J; Sugg J; Tudor IC; Huizing M; Young R; Abramson V; Bose R; Hart L; Chan S; Cameron D; Wright GS; Graas MP; Neven P; Rocca A; Russo S; Krop IE
Breast Cancer Res Treat; 2021 May; 187(1):155-165. PubMed ID: 33591468
[TBL] [Abstract][Full Text] [Related]
79. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.
Yamamoto Y; Iwata H; Ueno T; Taira N; Kashiwaba M; Takahashi M; Tada H; Tsugawa K; Toyama T; Niikura N; Hara F; Fujisawa T; Yoshinami T; Saji S; Takano T; Masuda N; Morita S; Toi M; Ohno S
Jpn J Clin Oncol; 2018 Sep; 48(9):855-859. PubMed ID: 30020510
[TBL] [Abstract][Full Text] [Related]
80. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
Kong A; Rea D; Ahmed S; Beck JT; López López R; Biganzoli L; Armstrong AC; Aglietta M; Alba E; Campone M; Hsu Schmitz SF; Lefebvre C; Akimov M; Lee SC
Oncotarget; 2016 Jun; 7(25):37680-37692. PubMed ID: 27129177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]